Wild type ATTR amyloidosis (formerly known as senile systemic amyloidosis ) is a slowly progressive disease. The symptoms usually start after age 65. This condition is not hereditary, and it is far more common in men than in women. No-one knows just how common symptomatic wild type ATTR amyloidosis really is but it is almost certainly underdiagnosed at present. This diagnosis may become more common in future as the population ages and diagnostic methods continue to improve.
People with this condition do not have a mutation in the TTR gene and the amyloid fibrils are made up of normal, “wild type” TTR. These types of amyloid deposits are found at autopsy in 1 in 4 people over age 80, but in most cases they do not appear to cause any symptoms. Some patients with small ATTR amyloidosis deposits in the heart and minimal symptoms may not require any treatment.
Symptoms of wild type ATTR amyloidosis result from stiffening of the heart due to amyloid deposits (restrictive cardiomyopathy). These symptoms may include:
shortness of breath, sometimes just after mild exertion
palpitations and abnormal heart rhythms, most frequently atrial fibrillation or atrial flutter
leg swelling (oedema)
weight loss
nausea
fatigue
dizziness and collapse (syncope or fainting), which may occur after exertion, or after eating
disrupted sleep
angina (chest pain)
Almost 50% of patients with wild type ATTR amyloidosis experience carpal tunnel syndrome – tingling and pain in the wrists, pins and needles in the hands. Carpal tunnel syndrome often appears 3-5 years before the symptoms of heart disease.
It not clear at present just how commonly the deposits actually do lead to symptomatic disease. Recent developments with diagnostic tests such as cardiac magnetic resonance (CMR) have greatly improved the detection of amyloid in the heart during life. This has led to the belief that wild type ATTR amyloidosis may be far more common than was previously thought. Cardiologists are gradually becoming more aware that wild type amyloidosis may cause otherwise unexplained heart failure and are referring these patients more frequently to the NAC.
This is demonstrated in the following NAC statistics :
Up until 2001 wild type ATTR amyloidosis was diagnosed in just 1 out of every 200 (0.5%) of patients seen at the NAC.
In 2016 it accounted for nearly 1 in 5 (18%) of NAC patients diagnosed with amyloidosis – a 40 fold increase!
Patients with ATTR in the heart often have fewer symptoms than those with AL amyloidosis in the heart, and wild type ATTR amyloidosis usually progresses slowly.
Information about COVID-19 (corona) for patients with ATTR amyloidosis is available on the National Amyloidosis Centre website – see here.
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish.AcceptRejectRead More
Privacy & Cookies Policy
Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
Wild type ATTR amyloidosis
Wild type ATTR amyloidosis (formerly known as senile systemic amyloidosis ) is a slowly progressive disease. The symptoms usually start after age 65. This condition is not hereditary, and it is far more common in men than in women. No-one knows just how common symptomatic wild type ATTR amyloidosis really is but it is almost certainly underdiagnosed at present. This diagnosis may become more common in future as the population ages and diagnostic methods continue to improve.
People with this condition do not have a mutation in the TTR gene and the amyloid fibrils are made up of normal, “wild type” TTR. These types of amyloid deposits are found at autopsy in 1 in 4 people over age 80, but in most cases they do not appear to cause any symptoms. Some patients with small ATTR amyloidosis deposits in the heart and minimal symptoms may not require any treatment.
Symptoms of wild type ATTR amyloidosis result from stiffening of the heart due to amyloid deposits (restrictive cardiomyopathy). These symptoms may include:
Almost 50% of patients with wild type ATTR amyloidosis experience carpal tunnel syndrome – tingling and pain in the wrists, pins and needles in the hands. Carpal tunnel syndrome often appears 3-5 years before the symptoms of heart disease.
It not clear at present just how commonly the deposits actually do lead to symptomatic disease. Recent developments with diagnostic tests such as cardiac magnetic resonance (CMR) have greatly improved the detection of amyloid in the heart during life. This has led to the belief that wild type ATTR amyloidosis may be far more common than was previously thought. Cardiologists are gradually becoming more aware that wild type amyloidosis may cause otherwise unexplained heart failure and are referring these patients more frequently to the NAC.
This is demonstrated in the following NAC statistics :
Patients with ATTR in the heart often have fewer symptoms than those with AL amyloidosis in the heart, and wild type ATTR amyloidosis usually progresses slowly.
More on diagnosis and treatment of wild type ATTR amyloidosis.
Coronavirus Update
Information about COVID-19 (corona) for patients with ATTR amyloidosis is available on the National Amyloidosis Centre website – see here.